Regeneron (REGN) has received a new Buy rating, initiated by HSBC analyst, Yifeng Liu.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yifeng Liu has given his Buy rating due to a combination of factors that highlight Regeneron’s potential for growth beyond current market expectations. The analyst points to the accelerating uptake of Eylea HD in the short term and significant oncology catalysts expected in 2026 as key drivers for re-rating potential. Liu believes that despite recent challenges, such as the adoption issues with EYLEA HD and pipeline setbacks, Regeneron can surpass the anticipated mid-single digit revenue growth from 2025 to 2030.
Regeneron’s potential to exceed market expectations is further supported by regulatory advancements for EYLEA HD and promising clinical readouts from its oncology pipeline. The resolution of regulatory risks associated with EYLEA HD could lead to its accelerated adoption by 2026. Additionally, the upcoming Fianlimab + Libtayo readout in frontline melanoma could enhance the company’s competitive position in the LAG-3/PD-1 combination therapy market. Liu values Regeneron’s R&D platform highly, given its track record of discovering blockbuster drugs, which suggests further growth opportunities. The target price of USD 890 is derived using an adjusted present value calculation, indicating a 20.8% upside potential, thus justifying the Buy rating.
In another report released on November 20, Canaccord Genuity also maintained a Buy rating on the stock with a $850.00 price target.